Floatz logo

Ruxolitinib

Accelerated Phase Chronic Myeloid Leukemia

University Health Network, TorontoSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Accelerated Phase Chronic Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
University of Illinois at Chicago
Phase 2BBB
CYCLOSPORIN A
University of Michigan Rogel Cancer Center
Phase 2BBB
Cyclophosphamide
University of Illinois at Chicago
Phase 2BBB
METHOTREXATE
University of Michigan Rogel Cancer Center
Phase 2BB
TACROLIMUS
University of Michigan Rogel Cancer Center
Phase 2BB

View all 46 →

Same molecule, other indications

Ruxolitinib is also rated in:

primary myelofibrosisDormant
BBB
Indicative ·
73 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
70 / 100
View asset →
graft versus host diseaseDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →